Cannabis for Chronic Diarrhea
What the evidence actually says about using cannabis, THC, and CBD to manage chronic diarrhea from various causes.
Cannabis slows gut motility — that's basic pharmacology, not folklore. But 'slowing the gut' is not the same as 'treating chronic diarrhea.' The best evidence is for diarrhea tied to IBD or IBS, and even there cannabis mostly improves symptoms and quality of life, not the underlying disease. For most other causes of chronic diarrhea, the human data is thin to nonexistent. Loperamide is cheaper, better-studied, and doesn't get you high. Talk to a GI doc before self-treating.
Plain-language summary
Chronic diarrhea means loose or frequent stools lasting more than about four weeks. It has many causes: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS-D), microscopic colitis, bile acid malabsorption, celiac disease, infections, medications, and more. The right treatment depends on the cause.
Cannabis interacts with the gut through the endocannabinoid system. CB1 and CB2 receptors are expressed throughout the GI tract, and activating them tends to slow motility and reduce secretion [1][2]. That's why cannabis can make stools firmer and less frequent. But slowing the gut is a symptomatic effect — it doesn't fix what's actually wrong.
The strongest human data on cannabis and diarrhea comes from IBD trials, where cannabis improves symptoms and quality of life but does not appear to heal inflammation [3][4]. For most other causes of chronic diarrhea, we simply don't have good clinical trials.
This article is not medical advice. Chronic diarrhea can signal serious disease. See a clinician before self-treating.
What probably works (relatively speaking)
Symptomatic relief in IBD. Multiple small randomized trials in Crohn's disease have shown that inhaled or oral THC-rich cannabis improves patient-reported symptoms, including diarrhea, abdominal pain, and appetite, and improves quality of life Weak / limited [3][5]. A 2013 Israeli RCT by Naftali et al. found clinical improvement in Crohn's symptoms with smoked cannabis, though inflammatory markers did not consistently improve [3]. Follow-up studies have reinforced the symptom-benefit / no-mucosal-healing pattern [4].
Mechanism is real. CB1 agonism slows small-bowel and colonic transit; this is demonstrated in both animal and human physiology studies Strong evidence [1][2]. So the pharmacology of 'THC firms stools' is not folklore. What's uncertain is whether that translates to durable clinical benefit for chronic diarrhea specifically.
What might work
IBS-D. The endocannabinoid system is plausibly involved in IBS, and a few small trials of dronabinol (synthetic THC) have shown modest effects on colonic motility and, in some patients, symptom improvement Weak / limited [6]. Results are mixed and effect sizes are small.
Cannabis in place of opioids for motility control. In patients who currently rely on loperamide or opioid antidiarrheals and tolerate them poorly, low-dose THC is pharmacologically a reasonable alternative because CB1 activation shares downstream effects with mu-opioid activation on gut transit Weak / limited [2]. But this has not been tested in head-to-head trials for chronic diarrhea.
CBD alone. Preclinical data suggest CBD reduces intestinal inflammation and hypermotility in animal models Weak / limited [7]. A small human trial of CBD-rich extract in ulcerative colitis was largely negative for the primary endpoint [8]. Not a reliable antidiarrheal in humans on current data.
What doesn't work / weak or absent evidence
- 'Indica for diarrhea, sativa for constipation.' Folklore. The indica/sativa distinction does not reliably predict pharmacological effects on the gut No data.
- Cannabis for infectious diarrhea (C. difficile, traveler's diarrhea, viral gastroenteritis). No evidence of benefit. Slowing gut transit during a toxin-mediated infection can be actively harmful No data.
- Cannabis for chemotherapy-induced diarrhea. Cannabinoids are used for chemo-induced nausea, but there is no meaningful human evidence for chemo-induced diarrhea No data.
- Cannabis as a disease-modifying treatment in IBD. Repeatedly, trials show symptom benefit without objective improvement in inflammation, endoscopy, or biomarkers [evidence:strong that it does not modify disease] [4].
- High-dose or heavy chronic use to control diarrhea. Risks (see below) escalate quickly, and paradoxically, heavy chronic cannabis use can cause cannabinoid hyperemesis syndrome, which includes GI symptoms [9].
What we don't know
- Optimal THC:CBD ratio for GI symptom control.
- Whether oral, sublingual, or inhaled routes give the best diarrhea-specific outcomes.
- Long-term effect on gut microbiome and mucosal immunity.
- Whether cannabis helps bile acid diarrhea, microscopic colitis, or post-cholecystectomy diarrhea — essentially no trial data exist.
- Whether any subgroup (by genotype, disease type, or endocannabinoid tone) responds preferentially.
Comparison with standard treatments
Standard first-line treatments for chronic diarrhea depend on cause:
- Loperamide (Imodium): peripheral mu-opioid agonist, does not cross the blood-brain barrier at normal doses, decades of safety data, cheap, OTC in most countries [10].
- Diphenoxylate/atropine (Lomotil): prescription, similar mechanism.
- Bile acid sequestrants (cholestyramine, colesevelam): for bile acid diarrhea.
- Rifaximin: for IBS-D and small intestinal bacterial overgrowth.
- Eluxadoline, alosetron: for IBS-D specifically.
- Disease-specific therapy: 5-ASA, steroids, biologics for IBD; gluten-free diet for celiac; etc.
Cannabis has not been shown superior to any of these for any specific diarrhea indication. Its niche, if any, is as an add-on for patients with IBD or IBS-D whose symptoms and quality of life remain poor on standard therapy — a use case supported by small trials, not large ones [3][5].
Risks and practical cautions
- Cannabinoid hyperemesis syndrome (CHS). Long-term heavy cannabis use can cause cyclic vomiting, abdominal pain, and GI upset that paradoxically mimics or worsens the very symptoms patients are trying to treat [9].
- Impairment. THC causes cognitive and psychomotor impairment; not suitable if you need to drive, work safety-sensitive jobs, or care for others while dosed.
- Dependence and withdrawal. Regular use can produce cannabis use disorder in a meaningful minority of users [11].
- Drug interactions. CBD in particular inhibits CYP450 enzymes and interacts with warfarin, some antiepileptics, and immunosuppressants used in IBD [12].
- Masking serious disease. Chronic diarrhea can be the presenting symptom of IBD, celiac, colorectal cancer, or chronic infection. Self-treating with cannabis without a workup risks delayed diagnosis.
- Pregnancy and breastfeeding. Avoid.
This article is educational and is not medical advice. Talk to a gastroenterologist or your prescribing clinician before using cannabis to manage chronic diarrhea, especially if you have IBD, are on immunosuppressants, or have not had a diagnostic workup.
Sources
- Peer-reviewed Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & Therapeutics. 2010;126(1):21-38.
- Peer-reviewed Camilleri M. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterology & Motility. 2018;30(9):e13370.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276-1280.
- Peer-reviewed Kienzl M, Storr M, Schicho R. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology. 2020;11(1):e00120.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS ONE. 2021;16(2):e0246871.
- Peer-reviewed Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141(5):1638-1647.
- Peer-reviewed Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE. Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clinical Science. 2017;131(21):2611-2626.
- Peer-reviewed Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflammatory Bowel Diseases. 2018;24(4):714-724.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review. Journal of Medical Toxicology. 2017;13(1):71-87.
- Peer-reviewed Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clinical Gastroenterology and Hepatology. 2017;15(2):182-193.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.